Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research
暂无分享,去创建一个
P. Williamson | J. Kirkham | L. Wedderburn | B. Feldman | I. Lundberg | L. Pachman | D. Appelbe | L. Rider | A. Huber | P. Mathiesen | M. Beresford | T. Constantin | C. Pilkington | A. Aggarwal | L. Christopher‐Stine | L. Mccann | S. Spinty | A. Ravelli | A. Reed | R. Russo | S. Maillard | R. Murphy | Annet van Royen-Kerkof | L. McCann
[1] J. Treat,et al. Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool–Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists , 2017, The British journal of dermatology.
[2] P. Lachenbruch,et al. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative In , 2017, Arthritis & rheumatology.
[3] P. Lachenbruch,et al. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis , 2017, Annals of the rheumatic diseases.
[4] L. Rider,et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease , 2017, Pediatric Rheumatology.
[5] Jane M Blazeby,et al. ORAL PRESENTATIONS , 1993, European Surgical Research.
[6] I. Sjaastad,et al. Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies , 2016, RMD Open.
[7] P. Williamson,et al. Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use , 2015, Trials.
[8] K. Main,et al. Validity of Self-Assessment of Pubertal Maturation , 2015, Pediatrics.
[9] J. Gottenberg,et al. Incidence and prevalence of inflammatory myopathies: a systematic review. , 2015, Rheumatology.
[10] F. Miller,et al. Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research , 2014, Current opinion in rheumatology.
[11] A. Rawat,et al. Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India , 2014, Clinical Rheumatology.
[12] L. Wedderburn,et al. Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research , 2014, Pediatric Rheumatology Online Journal.
[13] B. Feldman,et al. Health outcomes of pediatric rheumatic diseases. , 2014, Best practice & research. Clinical rheumatology.
[14] A. Martini,et al. PReS-FINAL-2012: Introducing a new approach to clinical care of juvenile dermatomyositis: the juvenile dermatomyositis multidimensional assessment report , 2013, Pediatric Rheumatology.
[15] I. Lundberg,et al. Registries in idiopathic inflammatory myopathies , 2013, Current opinion in rheumatology.
[16] J. Malley,et al. The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies , 2013, Medicine.
[17] A. Reed,et al. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis , 2011, Nature Reviews Rheumatology.
[18] R. Ramsey,et al. Measures of general pediatric quality of life: Child Health Questionnaire (CHQ), DISABKIDS Chronic Generic Measure (DCGM), KINDL‐R, Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales, and Quality of My Life Questionnaire (QoML) , 2011, Arthritis care & research.
[19] A. Reiff,et al. Preliminary criteria for global flares in childhood‐onset systemic lupus erythematosus , 2011, Arthritis care & research.
[20] R. Schneider,et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. , 2011, Rheumatology.
[21] M. Urowitz,et al. International consensus for a definition of disease flare in lupus , 2011, Lupus.
[22] L. Wedderburn,et al. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies , 2010, Rheumatology.
[23] N. Wulffraat,et al. The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis , 2010, Arthritis care & research.
[24] P. Mathiesen,et al. Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients. , 2010, Clinical and experimental rheumatology.
[25] B. Lie,et al. Long‐term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case–control study , 2010, Arthritis care & research.
[26] A. Martini,et al. Long‐term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients , 2010, Arthritis care & research.
[27] I. Sjaastad,et al. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. , 2009, Rheumatology.
[28] S. Prahalad,et al. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. , 2009, Arthritis and rheumatism.
[29] B. Feldman,et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood , 2008, The Lancet.
[30] A. Paller,et al. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. , 2008, Arthritis and rheumatism.
[31] L. Wedderburn,et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. , 2006, Rheumatology.
[32] B. Feldman,et al. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). , 2006, Rheumatology.
[33] L. Wedderburn,et al. Paediatric idiopathic inflammatory muscle disease: recognition and management. , 2005, Drugs.
[34] C. Duffy. Health outcomes in pediatric rheumatic diseases , 2004, Current opinion in rheumatology.
[35] N. Jones,et al. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire , 1993, Quality of Life Research.
[36] W. Kuis,et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. , 2003, Rheumatology.
[37] P. Lachenbruch,et al. Defining Clinical Improvement in Adult and Juvenile Myositis. , 2003, The Journal of rheumatology.
[38] B. Feldman,et al. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. , 2002, Rheumatic diseases clinics of North America.
[39] D. Isenberg,et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. , 2001, Rheumatology.
[40] B. Feldman,et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. , 2000, Arthritis and rheumatism.
[41] B. Feldman,et al. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. , 2000, The Journal of rheumatology.
[42] G. Bonsel,et al. Test-retest reliability of health state valuations collected with the EuroQol questionnaire. , 1994, Social science & medicine.